ESC. Update of the ESC Guidelines on Medical Therapy. John Camm. ICM Internationales Congress Center München
|
|
- Arabella Sara Bruce
- 5 years ago
- Views:
Transcription
1 ESC 2012 ICM Internationales Congress Center München Update on Consensus Statements on Management of Atrial Fibrillation European Heart Rhythm Association Update of the ESC Guidelines on Medical Therapy 2012 John Camm St. George s University of London United Kingdom
2 ESC 2012 ICM - Internationales Congress Center München Update on Consensus Statements on Management of Atrial Fibrillation European Heart Rhythm Association Update of the ESC Guidelines on Medical Therapy 2012 John Camm Conflicts of Interest: Consultant/Advisor/Speaker Advisor / Speaker : Astra Zeneca, Gilead, Merck, Menarini, Sanofi Aventis, Servier, Xention, Bayer, Boehringer Ingleheim, Bristol Myers Squibb, Daiichi, Pfizer, Boston Scientific, Biotronik, Medtronic, St. Jude Medical, Actelion, GlaxoSmithKline, InfoBionic, Incarda, Johnson and Johnson, Mitsubishi, Novartis, Takeda
3 Management of Atrial Fibrillation Focus of 2012 Update Anticoagulation risk stratification Use of novel oral anticoagulants (NOACs) Left atrial appendage occlusion/excision Pharmacological cardioversion (vernakalant) Oral antiarrhythmic therapy (dronedarone, and short term therapy) Left atrial catheter ablation European Heart Journal doi: /eurheartj/ehs253
4 New /Modified Recommendations Topic A B C I IIa IIb III Anticoagulation risk stratification Anticoagulation Left atrial appendage occlusion Pharmacological cardioversion Oral antiarrhythmic therapy Left atrial catheter ablation Total n (%) 12 (35%) 20 (59%) 2 (9%) 12 (35%) 17 (50%) 3 (9%) 2 (9%) European Heart Journal doi: /eurheartj/ehs253
5 Anticoagulation - General Recommendations for prevention of thromboembolism in nonvalvular AF - general Recommendations Class Level Antithrombotic therapy to prevent thromboembolism is recommended for all patients with AF, except in those patients (both male and female) who are at low risk (aged <65 years and lone AF), or with contraindications. The choice of antithrombotic therapy should be based upon the absolute risks of stroke/thromboembolism and bleeding and the net clinical benefit for a given patient. The CHA 2 DS 2 -VASc score is recommended as a means of assessing stroke risk in non-valvular AF. I A I I A A ESC Update on the Management of AF: European Heart Journal/EP- Europace 2012
6 Proportion of patients free of thromboembolism (%) Proportion of patients free of thromboembolism (%) CHADS 2 vs CHA 2 DS 2 VASc All patients with atrial fibrillation not treated with VKAs in Denmark CHADS 2 score = 0 Heart failure Hypertension Diabetes mellitus Age 75 years fulfilled the study inclusion criteria 100 CHADS 2 score = 0 Female sex Heart failure Hypertension Vascular disease Age years Diabetes mellitus Years of follow-up Years of follow-up Kaplan-Meier estimate of probability of remaining free of thromboembolism with CHADS 2 score 0 and 1. Only patients with CHADS 2 scores 0 and 1 were included, and patients were censored at death for causes other than thromboembolism Kaplan-Meier estimate of probability of remaining free of thromboembolism with CHA 2 DS 2 score 0 and 1. Only patients with CHA 2 DS 2 scores 0 and 1 were included, and patients were censored at death for causes other than thromboembolism Olesen JB et al, BMJ 2011;342:d124
7 CHA 2 DS 2 -VASc Assessment of Thromboembolic Risk Congestive heart failure/ 1 LV dysfunction Hypertension 1 Age 75 2 Diabetes mellitus 1 Stroke/TIA/TE 2 Vascular disease 1 (CAD, AoD, PAD) Age Sex category (female) 1 Score 0 9 Validated in 1084 NVAF patients not on OAC with known TE status at 1 year in Euro Heart Survey OR for stroke if: Female: 2.53 ( ), p=0.029; Vascular disease: 2.27 ( ), p=0.063 Score Annual stroke rate, % n Lip GYH, et al. Chest 2009 Olesen JB et al. BMJ 2011;342:124
8 Recommendations Class Level In patients with a CHA 2 DS 2 -VASc score of 0 (i.e., aged <65 years with lone AF) who are at low risk, with none of the risk factors, no antithrombotic therapy is recommended. In patients with a CHA 2 DS 2 -VASc score 2, OAC therapy with: adjusted-dose VKA (INR 2 3); or a direct thrombin inhibitor (dabigatran); or an oral factor Xa inhibitor (e.g., rivaroxaban, apixaban) d. is recommended, unless contraindicated. In patients with a CHA 2 DS 2 -VASc score of 1, OAC therapy with: adjusted-dose VKA (INR 2 3); or a direct thrombin inhibitor (dabigatran); or an oral factor Xa inhibitor (e.g., rivaroxaban, apixaban) d. should be considered, based upon an assessment of the risk of bleeding complications and patient preferences. I I IIa B A A d = pending EMA/FDA approval prescribing information is awaited European Heart Journal doi: /eurheartj/ehs253
9 Category W vs Placebo Stroke Prevention: Anticoagulant Effect Meta-analysis of stroke or systemic embolism Relative Hazard Ratio (95% CI) W vs Dabigatran 110 W vs Rivaroxaban ICH W vs W low dose W vs Aspirin W vs Aspirin + Clop W vs Ximelagatran W vs Dabigatran 110 W vs Rivaroxaban W vs Dabigatran 150 W vs Apixaban Favours Favours other warfarin Rx W vs Dabigatran 150 W vs Apixaban 5 W vs Dabigatran 110 W vs Rivaroxaban W vs Dabigatran 150 W vs Apixaban Major bleeding Favours Favours other warfarin Rx Modified from Camm AJ. EHJ 2009;30:2554 5
10 Anticoagulation - NOACs Recommendations for prevention of thromboembolism in nonvalvular AF - NOACs Recommendations Class Level When adjusted-dose VKA (INR 2 3) cannot be used in a patient with AF where an OAC is recommended, due to difficulties in keeping within therapeutic anticoagulation, experiencing side effects of VKAs, or inability to attend or undertake INR monitoring, one of the NOACs, either: a direct thrombin inhibitor (dabigatran); or an oral factor Xa inhibitor (e.g., rivaroxaban, apixaban) d is recommended. Where OAC is recommended, one of the NOACs, either: a direct thrombin inhibitor (dabigatran); or an oral factor Xa inhibitor (e.g., rivaroxaban, apixaban) d should be considered rather than adjusted-dose VKA (INR 2 3) for most patients with non-valvular AF, based on their net clinical benefit. ESC Update on the Management of AF: European Heart Journal/EP- Europace 2012 I IIa B A
11 Anticoagulation General Antiplatelet Agents Recommendations for prevention of thromboembolism in nonvalvular AF - general Recommendations Class Level When patients refuse the use of any OAC (whether VKAs or NOACs), antiplatelet therapy should be considered, using combination therapy with aspirin mg plus clopidogrel 75 mg daily (where there is a low risk of bleeding) or less effectively aspirin mg daily. IIa B European Heart Journal doi: /eurheartj/ehs253
12 Choice of Anticoagulant Atrial fibrillation Valvular AF* Yes Yes No (i.e. non-valvular AF) < 65 years and lone AF (including females) * Includes rheumatic valvular AF, hypertrophic cardiomyopathy, etc. ** Antiplatelet therapy with aspirin plus clopidogrel, or less effectively aspirin only, may be considered in patients who refuse any OAC No Assess risk of stroke (CHA 2 DS 2 -VASc score) 0 1** 2 Oral anticoagulant therapy Assess bleeding risk (HAS-BLED score) Consider patient values and preferences No antithrombotic therapy NOAC VKA European Heart Journal doi: /eurheartj/ehs253
13 Stroke / Systemic Embolism Rate (%) Dabigatran - Stroke and Systemic Embolism after Cardioversion 1983 cardioversions were performed in 1270 patients 4 2 3,5 3 p = ,5 2,5 2 p = With TEE prior to cardioversion Without TEE prior to cardioversion 1, , , D110 mg BID D150 mg BID Warfarin 0 Nagarakanti R et al. Circulation. 2011;123:
14 Anticoagulation - Cardioversion Recommendations for prevention of thromboembolism in nonvalvular AF Peri-cardioversion Recommendations Class Level For patients with AF of 48 h duration, or when the duration of AF is unknown, OAC therapy (e.g., VKA with INR 2-3 or dabigatran) is recommended for 3 weeks prior to and for 4 weeks after cardioversion, regardless of the method (electrical or oral/i.v. pharmacological). In patients with risk factors for stroke or AF recurrence, OAC therapy, whether with dose-adjusted VKA (INR 2-3) or a NOAC, should be continued lifelong irrespective of the apparent maintenance of sinus rhythm following cardioversion. I I B B ESC Update on the Management of AF: European Heart Journal/EP- Europace 2012
15 Stroke Outcome After Ablation vs AAD Therapy: Propensity-Matched Analysis Market Scan Research Database Ablation: n = 3194 AAD: n = 6028 Used in propensity-matched analysis: 801 pairs Follow-up: 27 months Stroke/TIA free survival HR = 0.60 ( ) AF, ablation AF, no ablation Log-rank p = Years 8.3% 14.1% Reynolds MR, et al. Circ Cardiovasc Qual Outcomes 2012;5 [epub ahead of press] Characteristic Age group, % > 80 Ablation n = AAD n = Men, % Hypertension, % Diabetes, % CHF, % CAD, % Stroke/TIA, % CHADS 2, % Warfarin Warfarin use decline to 50% in both groups
16 1 o efficacy endpoint 1 o safety endpoint PROTECT-AF Primary Safety and Efficacy Endpoints Major bleeding (IC, GI) Serious procedure related complications: Tamponade Device embolization Stroke Intention-to-treat analysis All strokes CV deaths Unexplained death Holmes DR, et al. Lancet 2009;374: RR = 1.69 ( ) Non-inferiority > 99.9% Superiority 90% Watchman 7.4 per 100 pt-yrs Warfarin 4.4 per 100 pt-yrs ,095 Days RR = 0.62 ( ) Non-nferiority > 99.9% Superiority 98.6% Warfarin 4.4 per 100 pt-yrs Watchman 3.0 per 100 pt-yrs Days 730 1,095
17 LAA Closure/Occlusion/Excision Recommendations for LAA closure/occlusion/excision Recommendations Class Level Interventional, percutaneous LAA closure may be considered in patients with a high stroke risk and contraindications for long-term oral anticoagulation. Surgical excision of the LAA may be considered in patients undergoing open heart surgery. IIb IIb B C European Heart Journal doi: /eurheartj/ehs253 European Heart Journal doi: /eurheartj/ehs253
18 Choice of Anti-coagulant Atrial fibrillation Valvular AF* Yes Yes No (i.e. non-valvular AF) < 65 years and lone AF (including females) * Includes rheumatic valvular AF, hypertrophic cardiomyopathy, etc. ** Antiplatelet therapy with aspirin plus clopidogrel, or less effectively aspirin only, may be considered in patients who refuse any OAC No Assess risk of stroke (CHA 2 DS 2 -VASc score) 0 1** 2 Oral anticoagulant therapy Assess bleeding risk (HAS-BLED score) Consider patient values and preferences No antithrombotic therapy NOAC VKA European Heart Journal doi: /eurheartj/ehs253
19 Intravenous Vernakalant Consistent Conversion Rates * ** ** ** CRAFT: Dosing was 2+3 mg/kg; data represents % converted at 60 min post last dose; AF duration 3-72 hours ACT I, III & IV: AF <7 days ACT II: Post CABG and valvular AF study; AF duration 3-72 hours ACT IV: A placebo group was not included in the ACT IV study ** P ** P
20 1 0 and 2 Efficacy Endpoint Results Time and Rate of Conversion from AF to SR Within 90 Minutes P < (Log-Rank test) 51.7% 10 min 25 min 35 min Vernakalant 24.1% 42.2% 45.7% Amiodarone 0.9% 2.6% 3.5% 5.2% Median Time To conversion in Vernakalant Responders was 11 minutes
21 Pharmacological Cardioversion Recommendations for pharmacological cardioversion of recent-onset AF Recommendations When pharmacological cardioversion is preferred and there is no or minimal structural heart disease, intravenous flecainide, propafenone, ibutilide, or vernakalant are recommended. In patients with AF 7 days and moderate structural heart disease (but without hypotension <100 mm Hg, NYHA class III or IV heart failure, recent [<30 days] ACS, or severe aortic stenosis) intravenous vernakalant may be considered. Vernakalant should be used with caution in patients with NYHA class I II heart failure. Class Level Intravenous vernakalant may be considered for cardioversion of postoperative AF 3 days in patients after cardiac surgery. IIb B I IIb A B European Heart Journal doi: /eurheartj/ehs253
22 yes Recent-onset AF Haemodynamic instability no electrical Patient/physician choice Cardioversion Recent Onset AF Emergency Elective pharmacological Structural heart disease Severe Moderate None Electrical cardioversion Intravenous amiodarone a Ibutilide should not be given when significant left ventricular hypertrophy ( 1.4 cm) is present. b Vernakalant should not be given in moderate or severe heart failure, aortic stenosis, acute coronary syndrome or hypotension. Caution in mild heart failure. c Pill-in-the-pocket technique preliminary assessment in a medically safe environment and then used by the patient in the ambulatory setting. Intravenous Ibutilide* vernakalant Intravenous amiodarone Intravenous flecainide propafenone vernakalant Intravenous amiodarone Pill-in-the pocket (high dose oral) flecainide propafenone European Heart Journal doi: /eurheartj/ehs253
23 Cumulative Hazard Cumulative Hazard Cumulative Hazard Cumulative Hazard Permanent versus Non-Permanent AF CV hospitalization or death % HR = 0.76 P < ATHENA Placebo 10 Dronedarone 0 Months CV hospitalization or death % 40 HR = 0.74 permanent P = Mean follow-up 21 5 months 10 Months PALLAS Stroke, MI, SEE or CV Death % HR = 2.29 P = Months CV hospitalization or death % HR = 1.95 P = Months Hohnloser SH et al. N Engl J Med. 2009;360: Connolly S et al. N Engl J Med. 2011;365:
24 Dronedarone Therapeutic Indication September 2009 MULTAQ is indicated in adult clinically stable patients with a history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate (see section 5.1). September 2011 MULTAQ is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile (see sections 4.3 and 4.4), Multaq should only be prescribed after alternative treatment options have been considered. MULTAQ should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure. Multaq (Dronedarone) SmPC Europe, September 2011
25 Details of the Hepatic Failure Cases Two cases of liver failure and transplant, year-old female History: intermittent AF, high BP & stable CAD. Received Dronedarone for 4.5m, no LFTs during this period. Concomitant medications: lisinopril, hydrochlorothiazide, bisoprolol, amlodipine, l-thyroxine, simvastatin, ASA, alendronic acid, tiotropium, formoterol. Presentation: 2 weeks prior to hospitalization was exhausted and tired. 1 week prior to admission discontinued Dronedarone, and on admission had jaundice, coagulopathy, transaminitis and hyperbilirubinemia; hepatic encephalopathy after 9 days. She was transplanted Pre-transplant workup no other cause 72-year-old female History: paroxysmal AF and Sjögren s syndrome. Received Dronedarone for 6 m, with no LFTs during this period. Concomitant medications: metoprolol, amlodipine, omeprazole, warfarin, alprazolam, calcium, biotin and multivitamins. Presentation: Developed weakness, abdominal pain, coagulopathy, transaminitis and hyperbilirubinemia. She was transplanted 1 month later. Pre-transplant no other cause. A liver biopsy prior to transplant revealed 60-70% necrosis. Joghetaei N, et al. Circ Arrhythm Electrophysiol. 2011;4: U.S. FDA Drug Safety Communication.
26 Reporting rate in patient-years x 1000 Dronedarone 2 year Post-marketing Safety Data Based on the estimated 440,000 patients treated with dronedarone up to 30 June 2011* Reporting rate per 1000 patient-years for serious adverse events per periodic safety update period 1 Jul Jan Feb Jul Aug Jan Feb Jun 2011 *Estimated. IMS/MIDAS Worldwide Monthly Database, Standard Units Sold until 30 June 2011, reported Aug 2011
27 FLEC-SL: Primary outcome (ITT) Flecainide 4 weeks vs long-term therapy 635 patients, Mean age 64 years, Primary outcome: Time to persistent AF, or death Monitored by telemetric ECG Kirchhof P et al Lancet Jul 21;380(9838):
28 Oral Antiarrhythmic Drugs Recommendations for oral antiarrhythmic agents Recommendations Dronedarone is recommended in patients with recurrent AF as a moderately effective antiarrhythmic agent for the maintenance of sinus rhythm. Class Level I A Short-term (4 weeks) antiarrhythmic therapy after cardioversion may be considered in selected patients e.g., those at risk for therapy associated complications. Dronedarone is not recommended in patients with permanent AF. III B IIb B European Heart Journal doi: /eurheartj/ehs253
29 Choice of Oral Antiarrhythmic Drug Minimal or no structural heart disease Significant structural heart disease Treatment of underlying condition and prevention of remodelling ACE-I / ARB / statin HHD CHD HF No LVH LVH sotalol dronedarone / flecainide / propafenone / sotalol dronedarone dronedarone amiodarone amiodarone amiodarone European Heart Journal doi: /eurheartj/ehs253
30 Pocket Guidelines European Heart Journal doi: /eurheartj/ehs253
31 Thank you for your attention
32 Thank you for your attention
What s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationDebate PRO. Dronedarone is an important drug in the management of paroxysmal atrial fibrillation. John Camm
ESC ICM - Internationales Congress Center München 2012 Atrial Fibrillation Controversies in Medical Treatment Debate Dronedarone is an important drug in the management of paroxysmal atrial fibrillation
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationקוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן
קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן INTRODUCTION The prevalence of atrial fibrillation (AF) is approximately 1.5 2% of the general population The arrhythmia is associated: with
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationThe Challenge and Opportunities for Stroke Prevention in AF
20th International Symposium on Thromboembolism October 2013 in London, United Kingdom Plenary Session I: Thromboembolic Stroke The Challenge and Opportunities for Stroke Prevention in AF John Camm St.
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationANTIPAF Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial
European Society of Cardiology Hotline Stockholm - Zone K 31 st August 2010 Placebo ARB Kumagai K, et al. JACC 2003 Discussant ANTIPAF Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial
More informationLeft atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationMANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017
MANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017 1 Faculty Disclosure Faculty: Peter Leong-Sit MSc, MD, FRCPC, FHRS Associate Professor, Western University Cardiologist, London Heart
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationGeriatric Grand Rounds
Geriatric Grand Rounds Tuesday, April 13, 21 12: noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More information2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation
European Heart Journal 2012 doi:10.1093/eurheartj/ehs253 ESC 2012 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation An update of the 2010 ESC Guidelines for the Management
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationManaging Stroke Prevention in AF: A Closer Look at Non-surgical Interventions
Managing Stroke Prevention in AF: A Closer Look at Non-surgical Interventions Riccardo Cappato, MD Humanitas University Electrophysiology & Arrhythmia Center Humanitas Research Institute, Milan & Gavazzeni
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationTreatment strategy decision tree
strategy decision tree strategy decision tree Confirmed diagnosis of AF Further investigations and clinical assessment including risk stratification for stroke/thromboembolism Paroxysmal AF Persistent
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationRelevant Advances in Atrial Fibrillation
Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisco Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Antiarrhythmic Drug
More informationHalf Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital
Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationDronedarone: Need to Perform a CV Outcome Safety Study
Dronedarone: Need to Perform a CV Outcome Safety Study Gerald V. Naccarelli M.D. Consultant: Glaxo-Smith-Kline, Pfizer, Sanofi, Boehringer-Ingelheim, Daiichi-Sankyo, Bristol Myers Squibb, Otsuka, Janssen
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationManagement of atrial fibrillation a holistic view - Prof. Dr. Martin Borggrefe Mannheim
a holistic view - Prof. Dr. Martin Borggrefe Mannheim Patients with atrial fibrillation (millions) 16 14 12 10 8 6 4 2 0 Management of atrial fibrillation Expected prevalence of apparent AF 5,1 5,1 5,9
More informationInnovations in AF Management
Innovations in AF Management Barry Boilson MD PhD FRCPI boilson.barry@mayo.edu Disclosures Relevant None financial relationship(s) with industry None Off Label Usage None Overview Mechanisms of AF AF as
More informationDr Chris Ellis. Consultant Cardiologist Auckland City Hospital Auckland
Dr Chris Ellis Consultant Cardiologist Auckland City Hospital Auckland 8:30-9:25 WS #189: Anticoagulation in AF 9:35-10:30 WS #201: Anticoagulation in AF (Repeated) Anticoagulation in Atrial Fibrillation
More informationHypertension and Atrial Fibrillation in 2017
Boma Inn, Eldoret, 24th 25thFebruary 2017 Hypertension and Atrial Fibrillation in 2017 Dr Mzee Ngunga Consultant Cardiologist Aga Khan University Hospital, Nairobi Objectives 1. Understand the relationship
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationANTICOAGULANTI Trattamento interventistico GIANLUCA BOTTO FESC, FEHRA, FAIAC UO ELETTROFISIOLOGIA
ANTICOAGULANTI Trattamento interventistico GIANLUCA BOTTO FESC, FEHRA, FAIAC UO ELETTROFISIOLOGIA Presenter Disclosure Information Research support: Boston Scientific, Medtronic; St., Bayer Healthcare,
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationConflicts of Interests
Advances in the Management of Atrial Fibrillation State of the Art in 2013 Overview of AF Stroke risk and anticoagulation Rate control Antiarrhythmic Drug Therapy Catheter ablation Conclusion Hugh Calkins
More informationOut with the old, in with The 2010 Atrial Fibrillation Guidelines
Out with the old, in with The 2010 Atrial Fibrillation Guidelines Kseniya Chernushkin B.Sc.(Pharm.), VCH/PHC Pharmacy Resident Mary Elliot B.Sc.(Pharm.), VCH/PHC Pharmacy Resident March 22, 2011 Outline
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationDevice detected AF and atrial high rate episodes
Device detected AF and atrial high rate episodes Professor Paulus Kirchhof University of Birmingham Institute of Cardiovascular Sciences SWBH and UHB NHS trusts, Birmingham, UK Department of Cardiovascular
More informationCombined catheter ablation and left atrial appendage closure as a. treatment of atrial fibrillation
Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation Giulio Molon, MD FACC, FESC, Fellow ANMCO Card Dept, S.Cuore hospital Negrar
More informationPractical Rate and Rhythm Management of Atrial Fibrillation
Practical Rate and Rhythm Management of Atrial Fibrillation pocket guide UPDATED FEBRUARY 2013 Adapted from the ACCF/AHA/HRS 2011 Focused Updates Incorporated into the ACC/AHA/ESC Guidelines for the Management
More informationSaudi Heart Association February 22, 2011
Pharmacological Therapy of Atrial Fibrillation: Recent Advances Dr Martin Green Professor of Medicine (Cardiology) University of Ottawa Saudi Heart Association February 22, 2011 Atrial Fibrillation Drugs
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More information4/25/2017. Atrial Fibrillation Review. John Evans, D.O. April 29 th, No disclosures
Atrial Fibrillation Review John Evans, D.O. April 29 th, 2017 No disclosures 1 Atrial Fibrillation Review: Learning Goals Stroke Prevention Rate Control Rhythm Control Drugs Ablation Cardioversion Atrial
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationStuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med
Stuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med None There s no reason to panic. While it is true that one of the crew members is ill, slightly. Absence of discrete P waves Chaotic
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Atrial Fibrillation Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic UC SF Division of
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationControversies in Risk Stratification
Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?
More informationRivaroxaban in Arrhythmology from Evidence Based Medicine to Real Life Experience: Patients Undergoing Cardioversion
Rivaroxaban in Arrhythmology from Evidence Based Medicine to Real Life Experience: Patients Undergoing Cardioversion Riccardo Cappato Arrhythmia and Electrophysiology Research Center, IRCCS Humanitas Research
More informationFred Kusumoto Professor of Medicine
Fred Kusumoto Professor of Medicine Faculty photo will be placed here Kusumoto.Fred@mayo.edu 2015 MFMER 3543652-1 Atrial Fibrillation Presentation Subtitle Here Mayo School of Continuous Professional Development
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationAtrial Fibrillation in the Emergency Department
Atrial Fibrillation in the Emergency Department Disclosures Edward Jauch, MD MS Research support National Institutes of Health funding (multiple trials) Novo Nordisk (drug in kind) STOP-IT Study Genentech
More informationStroke Prevention & Atrial Fibrillation. Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015
Stroke Prevention & Atrial Fibrillation Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015 Learning Outcomes What is Atrial Fibrillation? Why is Atrial Fibrillation important? What causes
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationSafety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup Martin W. Bergmann, Hüseyin Ince, Stephan Kische, Thomas Schmitz, Felix Meincke, Boris Schmidt, David Foley, Timothy
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationManagement of atrial fibrillation in diabetes
Stephen Dobbin 1 MBChB, MRCP, Cardiology SpR Miles Fisher 2 MD, FRCP, Consultant Physician Gerry McKay 2 BSc (Hons), FRCP, Consultant Physician 1 Department of Cardiology, Golden Jubilee National Hospital,
More informationPrimary Care Update in Medicine January 31 February 1, 2013 New Management Options for Patients with Atrial Fibrillation
Primary Care Update in Medicine January 31 February 1, 2013 New Management Options for Patients with Atrial Fibrillation Anne B. Curtis, MD, FACC, FHRS, FACP, FAHA Charles and Mary Bauer Professor, Chair,
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More information